To determine if recent cases of invasive group A streptococcal disease were caused by strains with a unique characteristic, 117 isolates of Streptococcus pyogenes from patients with a variety of diseases, including necrotizing fasciitis and toxic shock syndrome, were analyzed. Significant genomic heterogeneity was observed among selected isolates, as determined using pulsed-field gel electrophoresis. The frequency of the bacteriophage-associated streptococcal erythrogenic toxin genes A and C (speA and speC) among the isolates was 44% (49/112) and 34% (38/112), respectively. Fortythree percent of speA-positive isolates produced streptococcal erythrogenic toxin (SPE) A in vitro. Seventy-six percent (85/112) of isolates produced SPE B in vitro, and in contrast to SPE A, little variation in the concentration of SPE B in broth culture supernatants was detected. The genetic and phenotypic heterogeneity observed among isolates from recent cases of severe infection does not support a clonal basis for the resurgence of invasive streptococcal infections.
Infection with the group A streptococcus Streptococcus pyogenes results in various clinical manifestations, which vary significantly in severity. An increase in the incidence and severity of invasive infections caused by S. pyogenes since the late 1980s in the United States and many regions of Europe has reemphasized the pathogenic potential ofthis organism [1] . The current resurgence is particularly remarkable in that patients are typically middle-aged, healthy hosts without apparent predisposing factors or immune deficiencies. Despite significant study, the cause of episodic changes in the severity of streptoc occal infection remains unknown. Several factors have been proposed to contribute to the severity, type, and incidence of streptococcal infection, including changes in host immunity [2, 3] , socioeconomic conditions (including antibiotic therapy and prophylaxis) [4, 5] , and emergence of a more virulent strain [6] [7] [8] [9] [10] [11] [12] .
Streptococcal erythrogenic toxins A, B, and C (SPE A, B, and C), also known as streptococcal pyrogenic exotoxins, are among several extracellular products produced by S. pyogenes that may influence the severity of infection [13] . Since the original study by Yu and Ferretti [14] , several studies have also detennined the frequency of the bacteriophage-encoded speA [15, 16] and speC [17] genes among clinical isolates. In general, study results indicate a higher frequency of the speA gene in isolates from invasive disease episodes than in isolates from patients with noninvasive infections [7, 11] . However, despite this association, many isolates from patients with invasive infections lack the gene [11, 18, 19] . Unlike the phageencoded speA and speC genes, SPE B is chromosomally en..., coded and all strains of S. pyogenes have the gene, although not all strains produce the protein in vitro. Gerlach et al. [20] first recognized that SPE B was immunologically identical to streptococcal proteinase, and subsequent studies confinned that SPE B and proteinase are identical proteins [21, 22] . Caseinolytic activity of S. pyogenes is due specifically to SPE B [23] and has been associated with isolates from invasive disease episodes, including necrotizing fasciitis (NF) [18, 24] . In contrast to SPE A and SPE B, no association has been observed between strains possessing the speC gene or producing the protein in vitro and the severity 9f infection [14, 25] . Thus, indirect evidence suggests that SPE A and SPE B may each contribute to the virulence of S. pyogenes.
Coincident with the increase in incidence of invasive streptococcal disease has been a change in the predominant serotypes recovered from infected persons. The predominant serotypes isolated from US patients with severe streptococcal infections have changed recently from M3, M6, and M12, which were prominent in the early 1980s, to M1 [9, 18, [26] [27] [28] [29] . A similar shift, which coincided with increased incidences of severe infections, was observed in Sweden [2] , Norway [30] , and the United Kingdom [31] . These observations suggest that the current resurgence in the severity of streptococcal infection may partly be due to the reemergence of Ml strains. Furthennore, although it has been shown previously that significant heterogeneity exists even among isolates with identical serotypes [12, 32, 33] , recent results suggest a clonal basis for the resurgence in invasive disease episodes caused by M1 strains [7] .
The purpose of this study was to detennine if isolates involved in recent cases of severe streptococcal disease are genet-ically similar or have unique phenotypic properties with regard to the production of SPE A and SPE B in vitro. To achieve this objective, isolates from 112 patients were analyzed, including 30 isolates from patients with recent cases of NF and 37 from patients with recent cases oftoxic shock syndrome (TSS).
Materials and Methods
Bacterial strains. A total of 117 S. pyogenes isolates from 112 patients with a variety of clinical manifestations were studied (some isolates were obtained from different anatomic sites of the same patient). The patients were from 14 countries, although most (86) isolates were obtained from US patients during 1993 and 1994. Isolates designated 875-889, 922, and 924-928 were isolated in Oklahoma and were provided by K. S. Gilmore (Dept. of Public Health, Oklahoma City). Isolates designated 510,511,585, 592, 695, and 856-867 were provided by B. E. Robinson (Dept. of Public Health, Lansing, MI). Isolates 868-874, 890-921, and 923 were provided by one of us (D.L.S.) The remaining isolates were obtained from the streptococcal reference centers and World Health Organization laboratories [14] .
The serotype of74 isolates was determined (n is in parentheses):
, and M nontypeable (11) .
Isolates from disease episodes involving shock and organ failure were designated TSS strains. Isolates from infections involving the fascia were classified as NF strains. In cases in which symptoms of both TSS and NF were present, the isolate was classified as an NF strain.
Polymerase chain reaction (PCR) detection of speA and speC genes. PCR was used to detect the speA and speC genes in cell lysates prepared by the method of Hynes et a1. [34] . Thirty cycles of amplification were done in a DNA thermocycler (Perkin-Elmer Cetus, Norwalk, CT), with 1 min each of strand denaturation (94°C), annealing (48°C), and elongation (72°C). The PCR mixture (50 J-tL total) consisted of 1 J-tL of cell lysate, 1.7 J-tM each primer, 20 J-tM dNTPs, 4 mM Mg 2 +, and 0.5 U of Taq DNA polymerase (Promega, Madison, WI). Oligonucleotide primers were from Integrated DNA Technologies (Coralville, IA). For amplification of the speA, speB, and speC genes, the following primers were used: 5'-CACGAGAATGTGAAATCT-3' and 5'-GGTCCATTAGTA-TATAGTTGC-3' for speA, 5'-GGCGATTTCAGAATTGAT-GGC-3' and 5'-TAGTGCGTCAAGACGGAAG-3' for speB, and 5'-CCGAAATGTCTTATGAGGCC-3' and 5'-CCCTTCATT-TGGTGAGTC-3' for speC. Following amplification, a lO-J-tL aliquot was analyzed by agarose gel electrophoresis using 3% agarose (MetaPhor; FMC BioProducts, Rockland, ME). Each lysate was tested at least twice for each gene. If neither the speA or speC gene was detected, the lysate was tested using speB-specific primers (all isolates ofS. pyogenes have the speB gene) to ensure that the lysate contained amplifiable DNA. Lysates prepared from 4 characterized strains of S. pyogenes were used as controls: strain 631 (speAnegative, speC-positive), 640 (speA -positive, speC-negative), 642 (speA-positive, speC-negative), and 643.
Preparation qf culture supernatants. Isolates were grown in Todd-Hewitt dialysate broth [35] either overnight for the quantitation of SPE A or ,....,36 h for the analysis of SPE B. For SPE B, the isolates were grown anaerobically. The optical density at 600 nIn of each culture was determined, and a I-mL sample was transferred to a sterile microfuge tube and centrifuged to pellet the cells. The supernatant (900 J-tL) was then transferred to a sterile microfuge tube containing 30 J-tg of erythromycin and stored at -200°C. S. pyogenes NY5 was used as a positive control for SPE A production. For SPE B production, S. pyogenes NZ131 and an isogenic derivative, strain NZ 131speB- [22] , were used as positive and negative controls, respectively. Under these conditions, SPE B is present in the supernatant as the fully processed, proteolytic form of the protein.
ELISA. A sandwich ELISA was used to quantitate SPE A in culture supernatants. Protein A affinity-purified IgG rabbit antisera to SPE A (2.5 J-tg/well) was used to coat the wells of microtiter plates (Maxi-sorb; Nunc, Roskilde, Denmark) overnight at 4°C. The plates were then washed with 0.05% Tween 20 in PBS (buffer A) and blocked with 1% nonfat dry milk in PBS for 2 h at 37°C. Culture supernatant (50 J-tL) was added, and the plates were incubated for 1 h at 37°C. After the plates were washed, goat serum against SPE A (diluted 1:1000) was added, and the plates were incubated for 1 h at 37°C. After another wash, 50 J-tL of rabbit anti-goat alkaline phosphatase conjugate (Sigma, St. Louis), diluted 1: 1000 (vol/vol), was added to each well, and the plates were incubated for 1 h at 37°C. The plates were washed again, and pnitrophenyl phosphate, disodium (Sigma), was added at 1 mg/mL in 10% diethanolamine (pH 9.8) foreolor development. Standard curves were prepared using purified SPE A, and the concentration of SPE A in broth culture supernatant was determined by interpolation. The assay could detect as little as 2 ng/mL of SPE A in supernatant.
For analysis ofSPE B, 50 J-tL of supernatant, diluted 1:250 (vol/ vol) in carbonate-bicarbonate buffer (pH 9.2), was added to wells of a flat-bottom microtiter plate (Maxi-sorb, Nunc), and the plates were incubated overnight at 4°C. Following absorption, the wells were washed with buffer A. Unbound sites were blocked by the addition of 2% Tween 20 in PBS containing 3% bovine serum albumin, followed by incubation of the plates for 3 h at 37°C. After plates were washed w~th buffer A, 50 J-tL of rabbit anti-SPE B serum (provided by D. Gerlach, Institute of Experimental Microbiology, lena, Germany) diluted 1:1000 (vol/vol) in buffer A was added to each well, and the plates were incubated for 1 h at 37°C. The anti-SPE B serum was prepared with purified SPE B from S. pyogenes T-19. The plates were washed, and 50 J-tL of goat anti-rabbit IgG alkaline phosphatase conjugate (Sigma) diluted 1:5000 (vol/vol) in buffer A was added to each well, and the plates were incubated for 1 h at 37°C. The plates were washed again, and p-nitrophenyl phosphate, disodium (Sigma), was added at 1 mglmL in 10% diethanolamine (pH 9.8) for color development. The serum contains antibodies that react with the zymogen and fully processed proteolytic form of the protein in addition to several uncharacterized processing intermediates, as determined by Western immunoblotting. A serial dilution of purified SPE B (proteolytic form) was used to generate a standard curve. The concentration of SPE B is expressed in arbitrary units and was determined by interpolation and by dividing the value by the optical density of the culture at 600 nIn. No adjustment was made for the initial dilution of the supernatant.
Restriction fragment length polymorphism (RFLP). Chromosomal DNA was prepared as previously described [33] and di- Included in this study were several epidemiologically related isolates. In 2 instances, the concentration of SPE A in broth culture supernatant was different. The first instance involved a woman who developed and died ofpuerperal sepsis. Morphologically distinct isolates of S. pyogenes were recovered from her vagina (874) and blood (873). In addition, isolate 868 was recovered from the pharynx of her 2-year-old daughter. The banding patterns of isolates 868 and 874 were identical when restricted with SmaI or SfiI (figure IA). RFLP analysis using SmaI or SfiI showed that the blood isolate (873) differed from the vaginal isolate (874) by a single band (figure lA), indicating the isolates were similar. The vaginal isolate and the child's pharyngeal isolate (868) did not produce SPE A in vitro, although isolate 873 (blood) did (5.1.ng/mL) (figure IB). Western immunoblotting of concentrated supernatant from strains 873 Isolates were considered to represent the same strain if the number and sizes of all bands appeared identical. Banding patterns that differed by one or two bands were considered to be a subtype and were given a letter designation, representing the subtype, following the numeric designation, which represented the strain (e.g., I-A, I-B, etc.). Patterns that differed by more than two bands were considered to show unique strains. Proteolytic assay for SPE B. The proteolytic activity of SPE B was assessed by use of a casein-agar plate assay as described by Hynes and Tagg [36] . This assay is specific for the proteolytic activity of SPE B [23] .
SDS-PAGE and immunoblotting. SDS-PAGE of culture supernatant from clinical isolates was done using a discontinuous buffer system as previously described [37] . After electrophoresis, the proteins were either stained with Coomassie brilliant blue (Sigma) or transferred to nitrocellulose (Schleicher & Schuell, Keene, NH) by use of an electrophoresis unit (Transphor; Hoefer Scientific Instruments, San Francisco), as described by the manufacturer. After transfer, SPE A was detected by use ofrabbit antisera against SPE A, essentially as described [38] .
Streptokinase assay. A plate assay was used as previously described [39] to detect the production of streptokinase in broth culture supernatant.
Hyaluronidase assay. Hyaluronidase was detected by use of a plate assay as described [40] .
Results
PCR of speA, speB, and speC genes. peR was used to detect the speA and speC genes in cell lysates prepared from all 117 isolates. In cases where > 1 isolate was available from a patient, the amplification results were identical for every isolate, regardless of the anatomic site of collection or colony and 874 verified that only strain 873 produced SPE A under these conditions (data not shown).
A second instance of variation in SPE A production involved isolates 869, 870, 871, and 872, which were recovered from 3 siblings with different clinical outcomes of infection. Isolates 869 and 870 were recovered from siblings with noninvasive infections. Isolate 871 was recovered from an infected wound of a child who developed NF; isolate 872 was recovered from this patient's blood. The banding patterns of each of these isolates (869-872) were identical following digestion with SmaI (figure 2A). Digestion with 8ftI also JID 1996; 173 (April) resulted in identical banding patterns (data not shown). The 2 isolates from the sibling with NF (871 and 872) produced a high concentration of SPE A in vitro (90 ng/mL and 79 ng/mL, respectively) compared with isolates from siblings with noninvasive infections (869 and 870) (figure 2B). Western immunoblotting of concentrated culture supernatant from these 4 isolates confirmed the results (data not shown). Among the remaining epidemiologically related isolates, a similar concentration of SPE A was produced in broth culture supernatants.
SPE B production. The production of SPE B in vitro was assessed by use of a direct ELISA and a casein-agar plate assay. Each isolate was grown and tested by both assay methods a minimum of three times. The two assays were cognate with respect to SPE B production. Neither supernatant from the NZ131speB-strain nor mock-inoculated THY-D broth showed color development. Purified SPE B added to the supernatant from strain NZ13lspeB-gave similar results as purified SPE B diluted in coating buffer, suggesting that additional components present in the supernatant did not interfere with the quantitation of SPE B. Strain NZ 131 was used to estimate the variation inherent with this procedure: The mean concentration of SPE B in supernatants from the strain was 0.48 U (SD, 0.19 [40%]), as determined by testing the strain 12 times using 12 microtiter plates.
Among isolates from 112 patients, 86 (77%) produced SPE B (mean 0.42 ± 0.17); however, little variation in the concentration of SPE B in broth culture supernatants was observed ( In an attempt to observe phenotypic variation of SPE B production in vitro, selected strains were tested by single-colony passage on casein-agar plates; none of the SPE B nonproducers reverted to SPE B production during the study, and no producers of SPE B reverted to nonproducers. In instances in which> 1 isolate was available from 1 patient, there was absolute concordance (i.e., all strains isolated from a given patient either did or did not produce SPE B in vitro).
RFLP analysis. Significant genomic heterogeneity was observed, even among isolates from a limited time period and geographic area. Between 1991 and 1994, 21 isolates were recovered from patients in Oklahoma with invasive streptococcal infections. Twelve of these isolates were selected for RFLP analysis, and the results are summarized in table 3. RFLP analysis of the 12 isolates identified seven unique banding patterns, which were used to construct six sets of isolates. Set 0-lA contained 1 isolate (880) and was related to set 0-lB, which contained 4 identical isolates (881, 882, 885, and 888). Each member of set 0-1 had the speA gene but lacked the speC gene. Set 0-2 contained 3 isolates (875, 876, and 877); none possessed the speA or speC genes. The remaining isolates (883, 878, 879, and 884) had unique pulsed-field gel electrophoresis (PFGE) banding patterns.
Similar diversity was observed among 12 isolates from patients in Michigan who had invasive infections (856-867). These isolates were collected between 8 April and 8 July 1994, and the results are summarized in table 4. Four of the isolates (862, 863, 865, and 867) had identical banding patterns and were designated as set M-1A. Two isolates (859 and 864) identical to each other and similar to set M-1A were designated set M-1B. The remaining isolates had unique banding patterns ( figure 3 ). In general, significant genomic and phenotypic heterogeneity was observed among strains isolated from a limited geographic area within a short time.
With the exception of2 isolates from a patient with puerperal sepsis (described above), isolates from different anatomic sites or with different morphologic forms on blood agar plates (BAP) had identical PFGE banding patterns. Isolates 911-914 were isolated from 1 patient and had identical banding patterns. Similarly, isolates with different morphologies on BAP but that were isolated from 1 patient had identical banding patterns (897 and 898 and 890 and 891).
In 1 case, there was evidence of transmission between an asymptomatically infected physician and a patient. Isolate 890 was cultured from a patient who developed TSS and NF following surgery. This isolate's RFLP pattern was identical to isolate 894 from the patient's surgeon.
All strains were also assayed for the production of extracellular streptokinase and hyaluronidase. Streptokinase was produced by 97.5% of the strains, and hyaluronidase was produced by only 6%. No association could be made between production or lack thereof of these two extracellular proteins and disease.
Discussion
In this study, 117 isolates of S. pyogenes from 112 patients were collected. Specific genetic and phenotypic characteristics were analyzed to determine if isolates from recent episodes of invasive infections had a common and unique trait(s) partly responsible for the recent increase of invasive infections in the United States and elsewhere. About 25% of the 117 isolates were recovered during the 1980s from persons with a variety of streptococcal diseases; they were chosen to compare with the remaining 75% of the isolates, which were recovered since 1990 (most in 1992-1994) from persons with invasive disease. The isolates that we analyzed likely do not represent the breadth of strains in the community, sinc~we were particularly interested in isolates from patients with invasive infections. Thus, isolates from clusters of disease episodes and invasive infections are likely to be over-represented. Nonetheless, the group of isolates was diverse and contained isolates from 14 countries and 18 different M serotypes, including 22 M1 isolates, 13 M3 isolates, and 11 nontypeable M isolates.
The production of SPE A in vitro varied in 2 cases involving isolates from different anatomic sites (e.g., blood and vagina) and in isolates from siblings. However, the RFLP profiles, in vitro production of SPE A and SPE B, and presence of the phage-associated speA and speC genes among the remaining cases of epidemiologically related isolates were identical. These results indicate that, in general, the genetic and phenotypic parameters analyzed in this study were relatively stable.
Among the isolates analyzed in this study, 44% possessed the speA gene, a value higher than that detected by Yu and Ferretti (15%) among general streptococcal strains that were isolated between 1980 and 1988 and not associated with a particular disease [14] . Of interest, they found the gene in 45% and 48% of strains associated with scarlet fever and rheumatic fever, respectively [14] ; these values are nearly identical to the present study. In several US and European studies, recent isolates were more likely to have the phage-associated speA gene than were strains isolated in previous decades [3, 11, 18, 19, 27, 29] . The apparent increase in the frequency of the speA gene among clinical isolates of S. pyogenes coincided temporally with an increase in the incidence of invasive infections and prompted some investigators to suggest that SPE A is a causal factor in these invasive disease episodes. However, an increase in the frequency of Ml, M3, 856 857 858 859 861 862 866 Figure 3 . Ethidium bromide-stained pulsed-field gel electrophoresis of SmaI-digested chromosomal DNA from invasive isolates obtained in Michigan within 3-month period. and M18 serotypes in the United States also coincided with the increased severity of streptococcal infection [9, 18, [26] [27] [28] [29] . Similar results were obtained in Sweden, where remarkably, an Ml strains possessed the speA gene [2, 3] . In the investigation by Yu and Ferretti [14] in which only 15% of all isolates had the speA gene, 100% ofMl and 88% ofM3 strains isolated from patients with scarlet fever had the speA gene.
Thus, in the past, there was an association of M1 speApositive strains with scarlet fever and rheumatic fever, whereas today there is an association of Ml speA-positive strains with invasive infection. It remains unclear, however, ifthe increased incidence of invasive streptococcal disease is directly associated with SPE A or if the increased frequency of the speA gene among clinical isolates of S. pyogenes is only a consequence of the changing epidemiology of S. pyogenes to lysogenized M serotypes that harbor the speA gene.
Indirect evidence obtained in this study supports the idea that SPE A may be involved in severe streptococcal infections. Analysis of isolates with identical RFLP profiles from 3 siblings showed that only the invasive isolates produced SPE A in vitro; however, the speA gene was maintained in all of the isolates. Similarly, SPE A was produced in vitro only by an isolate from the blood of a puerperal sepsis patient; a similar isolate from the patient's 2-year-old daughter did not produce SPE A in vitro and did not cause invasive infection. The environmental and molecular factors involved in SPE A expression are poorly understood. It is unclear if SPE A production by these invasive strains occurred in response to environmental conditions encountered in the host during tissue invasion or if the protein contributed to the invasive ability of the strain. Nonetheless, these data implicate SPE A as a potential factor involved in severe invasive streptococcal infections.
It is clear, however, from the current study and others, that factors other than SPE A may be responsible for the develop-ment of TSS and NF, since in this study 31 % of isolates from patients with TSS and 37% from patients with NF did not possess either of the phage-encoded spe genes. In addition to SPE A, S. pyogenes can produce several other superantigens, including the mitogenic factor [41] , streptococcal superantigen [42] , and other uncharacterized superantigens [43] , which may influence the clinical outcome of infection. Moreover, the systemic effects often associated with these severe infections may be due to synergistic effects involving multiple streptococcal products [1] .
Previous studies associated the caseinolytic activity of SPE B in vitro with invasive disease episodes, including soft tissue infections [18, 24] . In those studies, the proportion of strains from invasive disease episodes that produced SPE B in vitro was similar to proportions for all isolates (noninvasive and invasive) analyzed in the current study. An association between SPE B production in vitro and the severity or invasiveness of infection was not observed in the current study. In addition, the proportion of isolates that produce the protein in vitro has remained similar during the previous 4 decades [19, 29, 36, [44] [45] [46] [47] , even as the severity of streptococcal infection has varied. It is unclear if isolates that do not produce SPE B in vitro are capable of secreting the protein in vivo or under alternate culture conditions. Routine laboratory. manipulations (i.e., freezing, multiple passage, and growth in various media) did not affect the production of SPE B in this study. Additional information regarding the mechanisms involved in SPE B expression is required to elucidate the molecular and environmental factors that appear to inhibit SPE B production in vitro among~25% of clinical isolates.
Overall, the genomic heterogeneity observed among strains analyzed in this study supports previous reports that demonstrated significant genomic heterogeneity even among strains expressing the same M serotype [32] , including MI strains [12, 33] . Our data indicate that the current resurgence of severe streptococcal infections is not due to the emergence or reemergence of a particularly virulent clone.
